Natural killer (NK) cells play a critical role in the body's immune system. Their unique ability to identify and destroy abnormal cells, while leaving healthy cells unharmed, make them a promising treatment option for various cancers and infectious diseases. NK and CAR-NK cells represent an attractive alternate modality with the potential to address shortcomings experienced by T cell and CAR T-based therapies. NK cell therapies also offer impressive feasibility as an off-the-shelf product, an enhanced safety profile with respect to cytokine release syndrome, neurotoxicity and graft-versus-host disease, and renewed promise where T cells have fallen short in the solid tumour setting.

In this webinar, we will:

• Discuss industry challenges and opportunities around NK cell therapy development and robust manufacturing preparation and infrastructure.
• Explore new, customizable, and scalable manufacturing platforms for NK cell therapies.
• Share an NK cell therapy platform case study and supporting data that can be applied in process development to streamline time to clinic, while mitigating challenges in manufacturing at commercial scale.